Journals / Journal of Human Rhythm / 2026 / Cilt: 1 Sayı: 3

Splenik Marjinal ZonLenfoma: Bir Olgu Sunumu

Pages
119–122
Publication Date
2015-12-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We would like to report a 84 year old woman with splenic marginal zone lymphoma who presented with weak ness and fatigue

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Marginal zone lymphomas (MZL) represent a group of low grade lymphomas whose cells originate from B lymphocytes normally present in marginal zone of the secondary lymphoid follicles.
📊
Key Findings & Data:According to World Healt Organization (WHO) classifi cation, MZL is described with three subtypes: extranodal MALT lymphoma, splenic MZL and nodal MZL.
💡
Conclusion & Impact:We would like to report a 84 year old woman with splenic marginal zone lymphoma who presented with weak ness and fatigue
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Splenik Marginal Zone Lenfoma · periferik yayma · kemik iliği akım sitometrisi

Abstract

Marginal zone lymphomas (MZL) represent a group of low grade lymphomas whose cells originate from B lymphocytes normally present in marginal zone of the secondary lymphoid follicles. According to World Healt Organization (WHO) classifi cation, MZL is described with three subtypes: extranodal MALT lymphoma, splenic MZL and nodal MZL. All threemarginal zone cell lymphomass hareimmuno-phenotypic, genetic and chromosomal similarities. Extranodal MALT lymphoma is an indolent disease that presents within volvement of mucosa associated lenfoid tissue (MALT) by a long-persistent local-ized mass with less frequent bone marrow and peripheral lymphnode involvement. We would like to report a 84 year old woman with splenic marginal zone lymphoma who presented with weak ness and fatigue

Özet

Marjinal zonlenfomalar(MZL) sekonderlenfoidfolliküllerinmarjinalzonunda bulunan B lenfositlerden köken alan düşük dereceli lenfomalardır. Dünya Sağlık Örgütü (WHO)'nün sınıfl andırmasına göre marjinalzonlenfomalar, ekstranodal MALT lenfoma, splenikMZL ve nodalMZL olmak üzere 3 alt gruba ayrılır. Her 3 grubun kromozomal, genetik ve immünfenotipik yönden benzerlikleri vardır. Ekstranodal MALT lenfomalar kemik iliği ve periferik lenf nodu tutuluşunun çok nadir görüldüğü, uzun süre lokalize bir kitle olarak kalan, mukoza ile ilişkili lenfoid dokuyu (MALT) tutan yavaş seyirli lenfomalardır. Biz burada halsizlik, yorgunluk şikayeti ile başvuran ve marjinalzonlenfoma tanısı konan 84 yaşındaki bayan olgu sunmayı amaçladık

🔖

Cite This Article

Ergenç, H., Varım, C., Çekdemir, D., Yaylacı, S., Can, F. İ., Tamer, A. (2015). Splenik Marjinal ZonLenfoma: Bir Olgu Sunumu. Journal of Human Rhythm, Cilt: 1 Sayı: 3, 119–122. https://ajindex.com/articles/1592547

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (27)

  1. Joshi M, Sheikh H, Abbi K, Long S, Sharma K, Tulchinsky M, Epner E.
  2. Marginalzonelymphoma: old, new, targeted, andepigenetictherapies.
  3. TherAdvHematol2012;3:275-290.
  4. ZinzaniPL. Themanyfaces of marginalzonelymphoma.
  5. HematologyAmSocHematolEduc Program 2012;2012:426-432.
  6. Arcaini L, Paulli M, Boveri E, Magrini U, Lazzarino M. Marginalzone-related
  7. neoplasms of splenicandnodalorigin. Haematologica 2003;88:80-93.
  8. Iannitto E, Ambrosetti A, Ammatuna E, Colosio M, Florena AM, Tripodo
  9. C, et al. Splenicmarginalzonelymphomawithorwithoutvillouslymphocyt
  10. es. Hematologic indingsandoutcomes in a series of 57 patients. Cancer;101:2050-2057.
  11. Parry-Jones N, Matutes E, Gruszka-Westwood AM, SwansburyGJ,
  12. WotherspoonAC, Catovsky D. Prognosticfeatures of spleniclymphomawith
  13. villouslymphocytes: a report on 129 patients. Br J Haematol 2003;120:759-
  14. Franco V, Florena AM, Iannitto E. Splenicmarginalzonelymphoma. Blood;101:2464-2472.
  15. Thieblemont C, Felman P, Berger F, Dumontet C, Arnaud P, Hequet O, et
  16. al. Treatment of splenicmarginalzone B-celllymphoma: an analysis of 81
  17. patients. ClinLymphoma 2002;3:41-47.
  18. Salido M, Baro C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, et
  19. al. Cytogenetic aberrationsandtheirprognosticvalue in a series of 330
  20. splenicmarginalzone B-celllymphomas: a multicenterstudy of theSplenic
  21. B-Cell LymphomaGroup. Blood 2010;116:1479-1488.
  22. Boveri E, Arcaini L, Merli M, Passamonti F, Rizzi S, Vanelli L, et al. Bone
  23. marrow histology in marginalzone B-celllymphomas: correlationwithclinic
  24. alparameters andflowcytometry in 120 patients. AnnOncol 2009;20:129-
  25. Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, BryonPA,
  26. et al. Non- MALT marginalzone B-celllymphomas: a description of
  27. clinicalpresentationand outcome in 124 patients. Blood 2000;95:1950-